Standout Papers

KRAS mutation: from undruggable to druggable ... 2015 2026 2018 2022 531
  1. KRAS mutation: from undruggable to druggable in cancer (2021)
    Lamei Huang, Zhixing Guo et al. Signal Transduction and Targeted Therapy
  2. Mechanisms of resistance to EGFR tyrosine kinase inhibitors (2015)
    Lihua Huang, Liwu Fu Acta Pharmaceutica Sinica B
  3. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance (2022)
    Kai Fu, Fang Wang et al. Journal of Hematology & Oncology
  4. CD39/CD73/A2AR pathway and cancer immunotherapy (2023)
    Shuanghong Yin, Kenneth K.W. To et al. Molecular Cancer
  5. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy (2025)
    Sijia Li, Kenneth K.W. To et al. Journal of Experimental & Clinical Cancer Research

Immediate Impact

21 from Science/Nature 61 standout
Sub-graph 1 of 23

Citing Papers

Endogenous stimuli-responsive separating microneedles to inhibit hypertrophic scar through remodeling the pathological microenvironment
2024 Standout
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
2 intermediate papers

Works of Liwu Fu being referenced

KRAS mutation: from undruggable to druggable in cancer
2021 Standout
Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo
2012
and 1 more

Author Peers

Author Last Decade Papers Cites
Liwu Fu 4752 5231 1322 201 9.5k
John S. Lazo 2877 7801 1436 311 13.2k
Kenneth K.W. To 3084 3862 1655 158 7.2k
Daniel B. Longley 4663 6849 2085 125 11.8k
Robert W. Robey 9073 7197 1203 158 13.6k
Martin Clynes 2703 5519 1625 295 8.8k
Jun O. Liu 2704 8746 1649 208 13.9k
Adrian M. Senderowicz 3756 4786 756 110 8.0k
T Tsuruo 5595 5345 909 155 9.6k
Maxwell Sehested 4352 6660 1357 152 9.7k
Kees Nooter 5379 3879 530 148 9.0k

All Works

Loading papers...

Rankless by CCL
2026